Compare · Head-to-head
CJC-1295 vs MK-677.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with CJC-1295, then use the table to confirm fit.
CJC-1295 is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01 · At a glance
| Decision factor | CJC-1295 | MK-677 |
|---|---|---|
| Primary fit | muscle growth & strength and fat loss & metabolism comparisons | muscle growth & strength and longevity & anti-aging comparisons |
| Evidence | Tier B | Tier C |
| Risk | high | med-high |
| Experience level | intermediate | advanced |
| Budget tier | mid | mid |
| Administration route | subcutaneous | oral |
02 · Use case & timing
| Decision factor | CJC-1295 | MK-677 |
|---|---|---|
| Goal fit | Muscle Growth & Strength, Fat Loss & Metabolism, GH Axis Optimization | Muscle Growth & Strength, Longevity & Anti-Aging, GH Axis Optimization |
| What users compare it for | Sustained GH and IGF-1 elevation; body composition modulation (long-horizon, not well-established for consumer outcomes). | Increased GH/IGF-1 signaling, appetite rise, and potential lean-mass increase in some human studies. |
| Onset timeline | Biomarker effects persist multiple days; IGF-1 elevations up to ~2 weeks after single dose. | GH rises acutely; IGF-1 and body-composition effects are tracked over weeks to months. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | CJC-1295 | MK-677 |
|---|---|---|
| Adverse effects | Injection-site reactions, headache, diarrhea, flushing, transient hypotension at higher doses. | Edema, increased appetite, insulin resistance, elevated fasting glucose, joint discomfort, and possible cardiovascular safety concerns. |
| Contraindications | GH-axis stimulation risks: glucose intolerance, theoretical neoplasia concerns with elevated IGF-1. | Use caution in diabetes, insulin resistance, edema-prone states, heart failure risk, and active malignancy. |
| Interaction notes | Monitor insulin/glucose sensitivity, thyroid axis, and cortisol/prolactin. Trials report no significant cortisol/prolactin/TSH/LH increases at 60 µg/kg single dose. | Combining with other GH-axis compounds increases endocrine complexity and may worsen glucose control. |
| Regulatory status | Not approved | Not approved |
| FDA flag | FDA compounding caution | FDA compounding caution |
| WADA status | WADA S2 | WADA S2 |
04 · Age & monitoring
| Decision factor | CJC-1295 | MK-677 |
|---|---|---|
| Supported age ranges | 25-34, 35-44, 45-54 | 25-34, 35-44, 45-54 |
| Life-stage note | Midlife is where GH-restoration framing is most often used, but evidence and long-term safety remain limited. | Most often discussed for younger and midlife adults, but metabolic and fluid-retention risks narrow the fit quickly with age. |
| Monitoring burden | high | high |
| Follow-up cadence | Reassess at startup and then roughly every few months if continuing. | More frequent early follow-up, then reassessment every few months if continued. |
05 · Cost & sourcing
| Decision factor | CJC-1295 | MK-677 |
|---|---|---|
| Typical cycle cost | $143.98 | No reliable estimate yet |
| Estimated monthly cost | $47.99 | No reliable estimate yet |
| Cost confidence | High confidence | No estimate |
06 · Before you buy
| Decision factor | CJC-1295 | MK-677 |
|---|---|---|
| Tracked vendor listings | 3 listings | 0 listings |
| Sourcing note | At least one listing is a blend rather than a clean standalone product, so review the product page carefully. | No tracked product page yet, so sourcing takes more manual review. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.